Banque Cantonale Vaudoise Raises Stock Holdings in Insulet Corporation $PODD

Banque Cantonale Vaudoise increased its stake in Insulet Corporation (NASDAQ:PODD) by 68.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,870 shares of the medical instruments supplier’s stock after purchasing an additional 4,004 shares during the period. Banque Cantonale Vaudoise’s holdings in Insulet were worth $2,071,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of PODD. Larson Financial Group LLC grew its position in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. bought a new position in shares of Insulet during the 4th quarter valued at about $26,000. Elyxium Wealth LLC bought a new position in shares of Insulet during the 4th quarter valued at about $28,000. DV Equities LLC purchased a new position in shares of Insulet during the 4th quarter valued at about $28,000. Finally, MV Capital Management Inc. purchased a new position in shares of Insulet during the 4th quarter valued at about $29,000.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Wall Street Zen lowered Insulet from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Canaccord Genuity Group decreased their price target on shares of Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Jefferies Financial Group lowered their price objective on shares of Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. Citigroup cut their price objective on shares of Insulet from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday, May 28th. Finally, Bank of America reduced their target price on shares of Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Twenty-two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $238.67.

Insider Transactions at Insulet

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.36% of the company’s stock.

Insulet Trading Up 2.9%

NASDAQ:PODD opened at $158.25 on Friday. The company has a market cap of $10.96 billion, a PE ratio of 36.80, a price-to-earnings-growth ratio of 1.07 and a beta of 1.13. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The company has a 50 day simple moving average of $159.09 and a two-hundred day simple moving average of $220.64. Insulet Corporation has a 12 month low of $138.79 and a 12 month high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.23. The firm had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s revenue was up 33.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Research analysts forecast that Insulet Corporation will post 6.46 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.